Consequently, BMS-986253—an anti-IL-8 antibody, is being tested in clinical trial in combination with Nivolumab (anti-PD-1) in patients with advanced solid tumors, including CRC (NCT03400332). The gene discussed is CXCL8; the disease is colorectal carcinoma.